|Bid||44.81 x 3000|
|Ask||53.49 x 1400|
|Day's Range||47.69 - 48.53|
|52 Week Range||46.29 - 58.90|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||0.96|
|Expense Ratio (net)||0.11%|
Value investors who are looking for a deal should look to international ETFs as global stocks are now trading at their lowest valuations in over two years. Major indices in Europe, Japan, Shanghai, Hong Kong, Argentina and Canada are all trading in correction territory, or off at least 10% from a recent high, while the U.S. is testing that precipice of after a selloff last week wiped out all of the S&P 500 and Dow Jones Industrial Average’s gains for the year, the Wall Street Journal reports. The selling and pessimism have also pushed the forward price-to-earnings ratio of the MSCI All Country World Index, which follows 23 developed and 24 emerging markets, to around 18, its lowest level since early 2016.
The global stock market has seen modest gains thus far this year, but that isn’t necessarily good news for the global economy, as the gains are more than entirely attributable to just one market.
Over the past several months, there has been one primary story in the global stock market: the U.S. has done very well, with major indexes rallying to records, while the rest of the world has done very badly, with some major economies entering bear markets.
U.S. equities and related ETFs have outperformed international markets, and the disparity may only continue to widen. “The yawning gap between US and international equity performance persists unabated,” ...
Among the emerging market (VEU) currencies, the Argentinian peso, Turkish (TUR) lira, Indonesia rupiah, and Indian rupee are declining to all-time lows. The US dollar is also strengthening against all major currencies, including those of emerging markets. As the US dollar strengthens and interest rates rise, the cost of servicing US debt for other countries goes up.
Is it time for one of the market’s most traditional hedges, which has fallen out of favor in 2018, to get another look?
After a bumpy ride in the first half of the year, global stocks are bouncing back, with iShares MSCI ACWI Index Fund (NASDAQ:ACWI), which targets the global stock market, up 1% last week. The U.S. stocks, as indicated by SPDR S&P 500 ETF (NYSEARCA:SPY), which tracks the S&P 500 index, is up 1.5% to start the second half versus 0.6% gain for Vanguard FTSE All-World ex-US ETF (NYSEARCA:VEU), which targets the international equity market excluding the United States.Source: Investment Zen via Flickr (Modified)
Stocks across the globe suffered their worst first half of a year since 2010, wiping out trillions of dollars from the MSCI’s 47-country world index. The iShares MSCI ACWI Index Fund (NASDAQ:ACWI), which targets the global stock market, has lost 0.3% year to date and Vanguard FTSE All-World ex-US ETF (NYSEARCA:VEU), targeting the international equity market excluding the United States, has shed about 3.9%.Source: Shutterstock
A few countries have been spared in the global massacre and will likely maintain their strength. As such, we have highlighted those country ETFs that delivered near to double-digit returns in the first half.
To build long-term wealth for the big-ticket items and retirement, you need to invest. Keeping your money in a CD paying 2% won’t cut it. So, if you’re an investor seeking a set-it-and-forget-it exchange-traded fund (ETF) portfolio, then low-fee, diversified index funds are your solution.
GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes various products for oral health, wellness, nutrition, and skin health. The Consumer Healthcare segment reported a 3% fall in its YoY (year-over-year) revenue to ~2.0 billion pounds in Q1 2018 compared to Q1 2017.
As exchange-traded funds (ETFs) have grown more popular among investors of all types, they have also become increasingly confusing and complicated. Particularly for those investors looking to invest in ETFs for the first time, it can be difficult to determine the best way to do so. Currently, there are close to 2,000 ETFs available to investors, covering a total of roughly $3 trillion in assets.
Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16. For 1Q18, analysts expect Novartis to see EPS of $1.28 on revenue of $12.6 billion.
Headquartered in London, AstraZeneca (AZN) is a pharmaceutical company with operations in over 100 countries. The company is involved in the research, development, and manufacture of drugs for both primary care and specialty care.
The excitement surrounding the tournament and its impact on the stock world has led investors to look at ETFs that could act as a proxy for the game.